EVT801, Kazia’s second programme, and capital markets

EVT801, Kazia’s second programme, and capital markets

Kazia Therapeutics — 9 videos in collection

In the third part of our Edison TV series on Kazia Therapeutics (KZIA), John Friend, CMO, and James Garner, CEO, discuss the company’s second pipeline asset, EVT801. EVT801 is a small molecule inhibitor of VEGFR3, which preclinical data have shown to be active against a broad range of tumour types and provided compelling evidence of synergy with immunoncology agents.

Additionally, Karen Krumeich, CFO, discusses Kazia’s focus on increasing awareness of the company in the US capital markets. 2022 is a data-rich year for Kazia and this episode concludes with an overview of the anticipated milestones and catalysts.


You may also be interested in these:

Cookie Policy Overview
Edison Group

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping us understand which section of the website you find more interesting and useful. See our Cookie Policy for more information.

Strictly necessary and functional

These cookies are used to deliver our website and content. Strictly necessary cookies relate to our hosting environment, and functional cookies are used to facilitate social logins, social sharing and rich-media content embeds.

Advertising

Advertising Cookies collect information about your browsing habits such as the pages you visit and links you follow. These audience insights are used to make our website more relevant.

Performance

Performance Cookies collect anonymous information designed to help us improve the site and respond to the needs of our audiences. We use this information to make our site faster, more relevant and improve the navigation for all users.